vs
Side-by-side financial comparison of BIOMERICA INC (BMRA) and Celldex Therapeutics, Inc. (CLDX). Click either name above to swap in a different company.
BIOMERICA INC is the larger business by last-quarter revenue ($1.2M vs $120.0K, roughly 10.1× Celldex Therapeutics, Inc.). BIOMERICA INC runs the higher net margin — -109.1% vs -67764.2%, a 67655.1% gap on every dollar of revenue. On growth, BIOMERICA INC posted the faster year-over-year revenue change (-26.0% vs -89.8%). Over the past eight quarters, BIOMERICA INC's revenue compounded faster (9.1% CAGR vs -12.3%).
Biomerica Inc. is a global medical technology company that develops, manufactures and markets diagnostic test kits and related medical products. Its portfolio covers gastrointestinal conditions, infectious diseases, food intolerances and point-of-care testing solutions, serving clinical labs, healthcare providers and retail healthcare segments across North America, Europe and Asia.
Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops targeted immunotherapies for hard-to-treat cancers and rare immunological diseases. Its pipeline covers antibody-drug conjugates, monoclonal antibodies and other novel therapies, serving patients with high unmet medical needs mainly across North America and Europe.
BMRA vs CLDX — Head-to-Head
Income Statement — Q2 2026 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $120.0K |
| Net Profit | $-1.3M | $-81.3M |
| Gross Margin | 4.2% | — |
| Operating Margin | -113.5% | -72628.3% |
| Net Margin | -109.1% | -67764.2% |
| Revenue YoY | -26.0% | -89.8% |
| Net Profit YoY | -38.9% | -72.7% |
| EPS (diluted) | $-0.45 | $-1.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | $120.0K | ||
| Q3 25 | $1.4M | $0 | ||
| Q2 25 | $749.0K | $730.0K | ||
| Q1 25 | $1.1M | $695.0K | ||
| Q4 24 | $1.6M | $1.2M | ||
| Q3 24 | $1.8M | $3.2M | ||
| Q2 24 | $1.1M | $2.5M | ||
| Q1 24 | $1.0M | $156.0K |
| Q4 25 | $-1.3M | $-81.3M | ||
| Q3 25 | $2.0K | $-67.0M | ||
| Q2 25 | $-1.5M | $-56.6M | ||
| Q1 25 | $-1.2M | $-53.8M | ||
| Q4 24 | $-950.0K | $-47.1M | ||
| Q3 24 | $-1.3M | $-42.1M | ||
| Q2 24 | $-1.4M | $-35.8M | ||
| Q1 24 | $-1.9M | $-32.8M |
| Q4 25 | 4.2% | — | ||
| Q3 25 | 30.7% | — | ||
| Q2 25 | -33.0% | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 26.7% | — | ||
| Q3 24 | 16.0% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | -14.7% | — |
| Q4 25 | -113.5% | -72628.3% | ||
| Q3 25 | -81.0% | — | ||
| Q2 25 | -209.1% | -8747.5% | ||
| Q1 25 | -108.1% | -9027.2% | ||
| Q4 24 | -60.7% | -4768.3% | ||
| Q3 24 | -75.7% | -1633.5% | ||
| Q2 24 | -136.6% | -1854.2% | ||
| Q1 24 | -196.7% | -26030.8% |
| Q4 25 | -109.1% | -67764.2% | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | -206.1% | -7753.4% | ||
| Q1 25 | -103.9% | -7740.4% | ||
| Q4 24 | -58.1% | -4007.8% | ||
| Q3 24 | -72.8% | -1320.0% | ||
| Q2 24 | -127.1% | -1434.8% | ||
| Q1 24 | -188.6% | -21030.8% |
| Q4 25 | $-0.45 | $-1.23 | ||
| Q3 25 | $0.00 | $-1.01 | ||
| Q2 25 | $-0.99 | $-0.85 | ||
| Q1 25 | $-0.48 | $-0.81 | ||
| Q4 24 | $-0.06 | $-0.71 | ||
| Q3 24 | $-0.63 | $-0.64 | ||
| Q2 24 | $-2.57 | $-0.54 | ||
| Q1 24 | $-0.11 | $-0.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.5M | $518.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.4M | $527.2M |
| Total Assets | $6.0M | $583.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.5M | $518.6M | ||
| Q3 25 | $3.1M | $583.2M | ||
| Q2 25 | $3.1M | $630.3M | ||
| Q1 25 | $3.1M | $673.3M | ||
| Q4 24 | $2.4M | $725.3M | ||
| Q3 24 | $2.8M | $756.0M | ||
| Q2 24 | $4.2M | $802.3M | ||
| Q1 24 | $5.3M | $823.8M |
| Q4 25 | $4.4M | $527.2M | ||
| Q3 25 | $5.2M | $598.4M | ||
| Q2 25 | $4.1M | $655.4M | ||
| Q1 25 | $5.5M | $703.0M | ||
| Q4 24 | $5.1M | $747.0M | ||
| Q3 24 | $5.3M | $785.9M | ||
| Q2 24 | $6.6M | $813.7M | ||
| Q1 24 | $7.8M | $838.6M |
| Q4 25 | $6.0M | $583.0M | ||
| Q3 25 | $6.9M | $648.4M | ||
| Q2 25 | $5.9M | $692.4M | ||
| Q1 25 | $7.4M | $739.5M | ||
| Q4 24 | $7.3M | $792.3M | ||
| Q3 24 | $7.9M | $823.2M | ||
| Q2 24 | $9.3M | $845.6M | ||
| Q1 24 | $10.3M | $868.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-991.0K | $-63.9M |
| Free Cash FlowOCF − Capex | — | $-65.2M |
| FCF MarginFCF / Revenue | — | -54350.8% |
| Capex IntensityCapex / Revenue | — | 1067.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-213.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-991.0K | $-63.9M | ||
| Q3 25 | $-268.0K | $-48.6M | ||
| Q2 25 | $-661.0K | $-44.0M | ||
| Q1 25 | $-1.0M | $-54.4M | ||
| Q4 24 | $-791.0K | $-32.5M | ||
| Q3 24 | $-1.3M | $-55.3M | ||
| Q2 24 | $-1.0M | $-29.3M | ||
| Q1 24 | $-1.8M | $-40.6M |
| Q4 25 | — | $-65.2M | ||
| Q3 25 | — | $-49.1M | ||
| Q2 25 | — | $-44.7M | ||
| Q1 25 | — | $-54.6M | ||
| Q4 24 | — | $-33.2M | ||
| Q3 24 | — | $-55.9M | ||
| Q2 24 | $-1.1M | $-29.6M | ||
| Q1 24 | — | $-41.0M |
| Q4 25 | — | -54350.8% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -6127.8% | ||
| Q1 25 | — | -7861.4% | ||
| Q4 24 | — | -2828.3% | ||
| Q3 24 | — | -1751.2% | ||
| Q2 24 | -95.5% | -1185.0% | ||
| Q1 24 | — | -26270.5% |
| Q4 25 | — | 1067.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 99.7% | ||
| Q1 25 | — | 38.1% | ||
| Q4 24 | — | 64.3% | ||
| Q3 24 | — | 17.1% | ||
| Q2 24 | 2.1% | 11.0% | ||
| Q1 24 | 0.0% | 220.5% |
| Q4 25 | — | — | ||
| Q3 25 | -134.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
